XTALPI-P (02228) plans to offer up to 264 million shares, raising approximately HK$1.125 billion in net proceeds.
Crystal Tai Holdings - P (02228) announced that on January 18, 2025, the company entered into a placement agreement with the placement agent...
XTALPI-P (02228) announced that on January 18, 2025, the company entered into a placement agreement with a placement agent, with the company intending to place up to 264 million shares through the placement agent, representing approximately 7.18% of the enlarged share capital. The placement price per share is HK$4.28, assuming all 264 million shares are fully subscribed, the net proceeds will be approximately HK$1.125 billion.
The directors believe that the placement is a good opportunity for the company to raise funds and expand its shareholder base. They also believe that the placement will strengthen the group's financial position and provide operational funds.
The announcement stated that the company intends to use the net proceeds from the placement primarily for continuous product iteration and upgrades, enhancing research and development capabilities and solution capabilities; promoting the commercial development of the company, strengthening external cooperation, expanding the company's scale and market share; potential investment opportunities, talent attraction and recruitment, supplementing operational funds, and general corporate purposes.
Related Articles

China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.
China Glass (03300) announced a net loss attributable to equity shareholders of approximately RMB 4.893 billion in 2025, representing an increase of about 4.58 times year-on-year.

CITIC SEC: The value of energy security is highlighted, and public utilities are expected to benefit from reevaluation

SSY GROUP(02005): Upatinib has been approved by the China Food and Drug Administration for registration as an active pharmaceutical ingredient for use in marketed preparations.

RECOMMEND

Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026

Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026

Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026


